guest ::
| Home > Publications database > Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. > print |
| Home > Publications database > Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. > print |
| 001 | 176959 | ||
| 005 | 20240229133726.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ejca.2021.08.019 |2 doi |
| 024 | 7 | _ | |a pmid:34521064 |2 pmid |
| 024 | 7 | _ | |a 0014-2964 |2 ISSN |
| 024 | 7 | _ | |a 0959-8049 |2 ISSN |
| 024 | 7 | _ | |a 1879-0852 |2 ISSN |
| 024 | 7 | _ | |a (1990) |2 ISSN |
| 024 | 7 | _ | |a 1879-2995 |2 ISSN |
| 024 | 7 | _ | |a (1965) |2 ISSN |
| 037 | _ | _ | |a DKFZ-2021-02192 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pouyiourou, Maria |0 P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2021 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1634106192_10608 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A360#LA:A360# |
| 520 | _ | _ | |a Single-site carcinoma of unknown primary (CUP) is recognised as a distinct favourable subtype in the European Society of Medical Oncology (ESMO) classification. There is broad consensus that these patients are candidates for local ablative treatment strategies with surgery and/or radiotherapy, but data on their outcomes are scarce.In this study, we have addressed the prospects of cure and prognostic factors in a retrospective cohort of 63 patients who were eligible for local treatment at our centre.Median event-free (EFS) and overall survival (OS) were 15.6 months and 52.5 months, respectively. Of 61 patients who received local treatment, 20 (32.8%) remained event-free over a median follow-up of 28 months. Baseline clinical parameters including affected organ, number, volume and histology of metastases had no significant impact on prognosis, whereas deleterious TP53 mutations and DNA copy number loss emerged as independent adverse risk factors with respect to EFS. Surgical treatment was associated with improved OS as compared to radiation-based therapy.Our study advocates to pursue localised treatment with surgery and/or radiotherapy whenever feasible and implies that genetic parameters might additionally determine the clinical course of single-site CUP patients. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a CUP (cancer of unknown primary) |2 Other |
| 650 | _ | 7 | |a Copy number loss |2 Other |
| 650 | _ | 7 | |a Oligometastasis |2 Other |
| 650 | _ | 7 | |a Prognosis |2 Other |
| 650 | _ | 7 | |a Radiotherapy |2 Other |
| 650 | _ | 7 | |a Single metastatic deposit |2 Other |
| 650 | _ | 7 | |a Surgery |2 Other |
| 650 | _ | 7 | |a TP53 |2 Other |
| 700 | 1 | _ | |a Wohlfromm, Timothy |0 P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28 |b 1 |u dkfz |
| 700 | 1 | _ | |a Kraft, Bianca |0 P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8 |b 2 |u dkfz |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 3 |u dkfz |
| 700 | 1 | _ | |a Stichel, Damian |b 4 |
| 700 | 1 | _ | |a von Deimling, Andreas |b 5 |
| 700 | 1 | _ | |a Delorme, Stefan |0 P:(DE-He78)3e76653311420a51a5faeb80363bd73e |b 6 |u dkfz |
| 700 | 1 | _ | |a Endris, Volker |b 7 |
| 700 | 1 | _ | |a Neumann, Olaf |b 8 |
| 700 | 1 | _ | |a Stenzinger, Albrecht |b 9 |
| 700 | 1 | _ | |a Krämer, Alwin |0 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |b 10 |u dkfz |
| 700 | 1 | _ | |a Bochtler, Tilmann |0 P:(DE-He78)c741dc7f974390ad4310349f29aac40b |b 11 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.ejca.2021.08.019 |g Vol. 157, p. 179 - 189 |0 PERI:(DE-600)1468190-0 |p 179 - 189 |t European journal of cancer |v 157 |y 2021 |x 0959-8049 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:176959 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)3e76653311420a51a5faeb80363bd73e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)c741dc7f974390ad4310349f29aac40b |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-28 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-28 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J CANCER : 2019 |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-28 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-28 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J CANCER : 2019 |d 2021-01-28 |
| 920 | 1 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l E010 Radiologie |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A360-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E010-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|